Impact of Depression on Thermoregulation

Description

The purpose of this study is to determine if, compared to non-depressed adults, differences exist in skin blood flow and sweating responses to passive heat stress in adults with clinically diagnosed depression, those with depression who are prescribed and taking SSRIs and those with depression who are prescribed and taking SNRIs.

Conditions

Depression, Selective Serotonin Reuptake Inhibitor

Study Overview

Study Details

Study overview

The purpose of this study is to determine if, compared to non-depressed adults, differences exist in skin blood flow and sweating responses to passive heat stress in adults with clinically diagnosed depression, those with depression who are prescribed and taking SSRIs and those with depression who are prescribed and taking SNRIs.

Thermoregulatory Responses to Heat Stress in Adults with Major Depressive Disorder with and Without Antidepressant Treatment

Impact of Depression on Thermoregulation

Condition
Depression
Intervention / Treatment

-

Contacts and Locations

University Park

Noll Laboratory, University Park, Pennsylvania, United States, 16802

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Non-depressed adults aged 18-40 years;
  • * OR adults aged 18-40 years with clinically diagnosed major depressive disorder according to DSM-V criteria not currently receiving antidepressant treatment;
  • * OR adults aged 18-40 years with clinically diagnosed major depressive disorder with at least 2 weeks of treatment with a selective serotonin reuptake inhibitor;
  • * OR aged 18-40 years adults with clinically diagnosed major depressive disorder with at least 2 weeks of treatment with a serotonin norepinephrine reuptake inhibitor;
  • * All participants will be asymptomatic and no signs/symptoms of disease according to the American College of Sports Medicine 10th edition Guidelines for Exercise Testing and Prescription (chest pain or pressure, dizziness, joint pain, and signs of cardiovascular disease);
  • * Systolic blood pressure 140 mmHg and diastolic pressure 90 mmHg at screening;
  • * Non-diabetic
  • * Not taking any other medications that might affect the physiological variables of interest (beta blockers, tricyclic antidepressants, antipyretics, diuretics, etc.);;
  • * Between the 20th and 80th percentiles for sex- and age-appropriate VO2max according to the American College of Sports Medicine 10th edition Guidelines for Exercise Testing and Prescription;
  • * English proficiency;
  • * Capable of providing informed consent.
  • * BMI \> 35
  • * Are pregnant or planning to become pregnant in the next 12 months;
  • * Concurrently participate in another study involving physical activity or weight loss;
  • * Plan to have surgery or relocate outside the area within the next year;
  • * Medications that could alter cardiovascular or thermoregulatory responses to exercise (beta blockers, antipyretics, tricyclic antidepressants, diuretics, etc.);
  • * Allergy to latex or adhesive;
  • * Tobacco use;
  • * Illegal/recreational drug use;
  • * Exertional chest pain or musculoskeletal pain;
  • * Contraindications to a maximal exercise test or an indication for early termination of the exercise test according to the American College of Sports Medicine 10th edition Guidelines for Exercise Testing and Prescription;
  • * Abnormal resting or exercise electrocardiogram (ECG);
  • * Any bleeding disorders, gastric ulcers, allergies to NSAIDS, asthma, kidney/liver disorders, and taking any other anticoagulants;
  • * History of Crohn's disease, diverticulitis, or similar gastrointestinal disease;
  • * Co-morbid psychiatric disorders (psychosis, schizophrenia, bipolar disorder, panic disorder, obsessive compulsive disorder, etc.);
  • * Active suicidal ideation (moderate or high suicidality);
  • * Use of psychoactive or psychopharmacological drugs other than SSRI and SNRIs within one year of participating.

Ages Eligible for Study

18 Years to 40 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Penn State University,

W. Larry Kenney, PRINCIPAL_INVESTIGATOR, The Pennsylvania State University

Study Record Dates

2025-09-01